The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes
Information source: University Hospital, Gentofte, Copenhagen
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetes Mellitus
Intervention: GIP-infusion (Other); Sodium-chloride (Other); GLP-2 infusion (Other)
Phase: N/A
Status: Completed
Sponsored by: University Hospital, Gentofte, Copenhagen
Summary
The purpose of this study is to determine whether Glucose-dependent Insulinotropic
Polypeptide (GIP) or Glucagon Like Peptide 2 (GLP-2) has an affect on the secretion of
Glucagon from the pancreas in patients with type 1 diabetes mellitus.
Clinical Details
Official title: The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes
Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science
Primary outcome: plasma-glucagon Area Under Curve at 0-90 min. and 90-180 min.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Caucasians over 18 years with type 1 diabetes (WHO criteria)
- Arginine test without rise in plasma C-peptide
- Normal blood Hemoglobin
- Informed consent
Exclusion Criteria:
- Liver disease
- Diabetic nephropathy
- Treatment with medications unpausable for 12 hours
Locations and Contacts
University Hospital, Gentofte, Hellerup, Capital Region 2900, Denmark
Additional Information
Starting date: January 2008
Last updated: February 12, 2009
|
